Therapeutic efficacy and safety of plasmapheresis in elderly patients with neuromyelitis optica spectrum disorder: a single-center observational study

被引:3
|
作者
Zhang, Weihe [1 ]
Jiao, Yujuan [2 ]
Cui, Lei [2 ]
Zhang, Yeqiong [2 ]
Jiao, Jinsong [2 ]
Jin, Ming [3 ]
Yuan, Wei [3 ]
You, Yang [4 ]
Wang, Renbin [2 ]
Peng, Dantao [1 ]
机构
[1] China Japan Friendship Hosp, Dept Neurol, 2 Yinghua, Beijing 100029, Peoples R China
[2] China Japan Friendship Hosp, Dept Neurol, Beijing, Peoples R China
[3] China Japan Friendship Hosp, Dept Ophthalmol, Beijing, Peoples R China
[4] 964 Hosp Peoples Liberat Army, Dept Neurol, Changchun, Peoples R China
关键词
efficacy; elderly; neuromyelitis optica spectrum disorder; plasma exchange; safety; PLASMA-EXCHANGE; DIAGNOSTIC-CRITERIA; OUTCOMES; MARKER; ATTACK; AGE;
D O I
10.1177/17562864231162420
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background:Neuromyelitis optica spectrum disorder (NMOSD) is a devastating autoimmune disorder with cycles of escalating relapse. Rates of diagnosis in the elderly are increasing. Therapeutic decision-making is more challenging in elderly patients due to multiple comorbidities and high risk of drug-induced side effects. Objective:This retrospective study assessed the efficacy and safety of standard plasma exchange (PLEX) treatment in an elderly population with NMOSD. Design:Seventy-six patients with NMOSD who received PLEX were apportioned to two groups as either elderly (> 60 years, n = 26) or young (<60 years) at the time of the first procedure. Methods:Therapeutic response was judged according to functional recovery at 6 months, as reflected by Expanded Disability Status Scale (EDSS) and visual outcome scale (VOS) scores. Results:The mean age of the 26 elderly patients was 67.7 +/- 7.9 years (range 60-87 years); the population was predominantly female (88.5%). PLEX sessions were generally well tolerated among the elderly. Compared with the young patients, the elderly had significantly more comorbidities and concomitant medications. Twenty-four (96.0%) elderly patients showed functional improvement at 6 months after PLEX, of which 15 (60.0%) experienced moderate-to-marked improvement. Six months after the initial PLEX treatment, the patients overall experienced a significant improvement in EDSS and VOS scores. Logistic regression showed that severe optic neuritis attack was a significant independent prognostic factor associated with poor PLEX response. The groups were comparable regarding overall or serious adverse events. The rate of transient hypotension was significantly higher in the elderly compared with the young. Conclusion:PLEX is an effective and safe therapy for elderly patients with NMOSD and should be considered a treatment option during NMOSD attacks. In the elderly, preventive measures against hypotension are recommended before PLEX.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] A Phase 3 Efficacy and Safety Study of Ravulizumab in Adult Patients With Neuromyelitis Optica Spectrum Disorder: Study Design and Methodology
    Pittock, Sean
    Allen, Kerstin
    Mashhoon, Yasmin
    Yountz, Marcus
    NEUROLOGY, 2022, 99 (23) : S4 - S5
  • [22] A Phase 3 Efficacy and Safety Study of Ravulizumab in Adult Patients with Neuromyelitis Optica Spectrum Disorder: Study Design and Methodology
    Pittock, S. J.
    Allen, K.
    Mashhoon, Y.
    Yountz, M.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 142 - 143
  • [23] Long-term Safety and Efficacy of Eculizumab in Neuromyelitis Optica Spectrum Disorder
    Wingerchuk, Dean M.
    Pittock, Sean J.
    Berthele, Achim
    Fujihara, Kazuo
    Kim, Ho Jin
    Levy, Michael
    Palace, Jacqueline
    Nakashima, Ichiro
    Terzi, Murat
    Totolyan, Natalia
    Viswanathan, Shanthi
    Wang, Kai-Chen
    Allen, Kerstin
    Fujita, Kenji P.
    Yountz, Marcus
    Armstrong, Roisin
    NEUROLOGY, 2020, 94 (15)
  • [24] Safety, Efficacy and Pharmacokinetics of Inebilizumab in African Americans with Neuromyelitis Optica Spectrum Disorder
    Bernitsas, E.
    Cimbora, D.
    Dinh, Q.
    Yan, L.
    She, D.
    Katz, E.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 149 - 150
  • [25] Neuromyelitis Optica Spectrum Disorder (NMOSD): Epidemiology, Treatments, and Outcomes in a Single Center
    Kadish, Robert
    Parker, Tavan
    Tanvir, Imran
    Royston, Minying
    Kielhorn, Adrian
    Biskupiak, Joseph
    Clardy, Stacey
    NEUROLOGY, 2020, 94 (15)
  • [26] A quarter-century report on neuromyelitis optica spectrum disorder in Thailand: A single-center tertiary care cohort
    Tisavipat, Nanthaya
    Lapanakoakiat, Saikaew
    Siengwattana, Pimkamon
    Rattanathamsakul, Natthapon
    Jitprapaikulsan, Jiraporn
    Prayoonwiwat, Naraporn
    Siritho, Sasitorn
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 63
  • [27] Efficacy and safety of mycophenolate mofetil for steroid reduction in neuromyelitis optica spectrum disorder: a prospective cohort study
    Akatani, Ritsu
    Chihara, Norio
    Koto, Shusuke
    Mori, Sotaro
    Kurimoto, Takuji
    Nakamura, Makoto
    Tachibana, Hisatsugu
    Otsuka, Yoshihisa
    Ueda, Takehiro
    Omori, Takashi
    Sekiguchi, Kenji
    Matsumoto, Riki
    IMMUNOLOGICAL MEDICINE, 2024, 47 (02) : 85 - 92
  • [28] Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective study
    Shaygannejad, V.
    Fayyazi, E.
    Badihian, S.
    Mirmosayyeb, O.
    Manouchehri, N.
    Ashtari, F.
    Asgari, N.
    JOURNAL OF NEUROLOGY, 2019, 266 (03) : 642 - 650
  • [29] Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective study
    V. Shaygannejad
    E. Fayyazi
    S. Badihian
    O. Mirmosayyeb
    N. Manouchehri
    F. Ashtari
    N. Asgari
    Journal of Neurology, 2019, 266 : 642 - 650
  • [30] Long-term efficacy and safety of rituximab in the treatment of neuromyelitis Optica Spectrum disorder
    Hayes, Michael T. G.
    Adam, Robert J.
    McCombe, Pamela A.
    Walsh, Michael
    Blum, Stefan
    MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2024, 10 (02)